Last reviewed · How we verify
RC88
At a glance
| Generic name | RC88 |
|---|---|
| Also known as | RC88 for Injection, The injectable RC88 |
| Sponsor | RemeGen Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer (PHASE2)
- A Phase I /IIa Study of RC88-ADC in Subjects With Advanced Malignant Solid Tumors (PHASE1, PHASE2)
- A Study to Assess the Safety and Tolerability of RC88 for Patients With Advanced Solid Tumours (PHASE1, PHASE2)
- A Study of RC148 As a Single Agent and Combination Therapy in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors (PHASE1, PHASE2)
- A Study of RC88 Combined With Sintilimab for Advanced Solid Tumours (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RC88 CI brief — competitive landscape report
- RC88 updates RSS · CI watch RSS
- RemeGen Co., Ltd. portfolio CI